Next Events in Series
Unlocking a New Generation of CNS-Targeted Therapies
Korea’s First Industry-Dedicated Forum Driving Innovation in Targeted, Mechanism-Differentiated CNS Therapies
December 1-3, 2026 | Boston, MA
8-10 December, 2026 | Incheon, South Korea
Harnessing Maturing Oligonucleotide Technologies to Unlock Undruggable CNS Targets with Enhanced RNA Chemistry & Innovative Delivery
Oligonucleotide R&D is accelerating, driven by advances in brain shuttle technologies, RNA chemistry, and growing clinical validation from leaders such as Alnylam Pharmaceuticals, Stoke Therapeutics, and Ionis Pharmaceuticals. At the same time, major investments, including Novartis into Arrowhead Pharmaceuticals, Biogen into City Therapeutics, and Roche into Manifold Bio, underscore CNS as a key frontier for these technologies, unlocking previously undruggable targets.
The Annual Oligonucleotides for CNS Summit brings together experts across CNS biology, oligo chemistry, RNA science, and DMPK. Attendees will explore the latest innovations advancing nucleic acid therapies for neurodegenerative, neuromuscular, rare, epileptic, and neurodevelopmental disorders.
This summit uniquely connects stakeholders at the intersection of oligonucleotides and CNS. Join leaders from Eli Lilly, Dyne Therapeutics, Creyon Bio, and more for three days of collaboration to accelerate RNA-targeted CNS therapies.
Attending Companies Included